Aldeyra R&D Day: reproxalap NDA resubmission H2 2024; positive preclinical data for ADX-246, ADX-629

Aldeyra Therapeutics, Inc.

Reproxalap NDA resubmission expected H2 2024, pending Phase 3 dry eye chamber trial results and FDA discussions.
ADX-629 showed statistically significant improvement in EASI, itching, and POEM scores in Phase 2 atopic dermatitis trial.
ADX-246 reduced hepatic acetaldehyde, histopathology, and liver enzymes in preclinical alcoholic hepatitis model.
ADX-629 enhanced GLP-1-mediated weight and fat mass loss in a diet-induced obesity mouse model.
Next-generation RASP modulators ADX-248 and ADX-246 demonstrated broad activity in preclinical inflammation models.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.